Marcus Anderson

Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.
Real Goods Solar, Inc. (NASDAQ:RGSE)

Can Real Goods Solar, Inc. (NASDAQ:RGSE) Close over $2.50?

Real Goods Solar, Inc. (NASDAQ:RGSE)

Real Goods Solar, Inc. (NASDAQ:RGSE) stock is up almost 9% as the as the stock attempts, for the fifth time this month, to close over $2.50. Volume is heavy today – over 4.2 million shares have traded by 11 AM EST which is almost nine times the listed daily average.

Last Thursday, October 26, Real Goods Solar, Inc. (NASDAQ:RGSE) announced that it had been selected by Solarize North Haven, a community-based residential solar purchasing cooperative, to bring solar electricity to homes and businesses in North Haven, Connecticut.

Solarize North Haven is a community-supported buying program that offers discounted group pricing, town-wide education and outreach support, as well as high quality equipment at reduced pricing and flexible financing to significantly reduce the cost of solar for North Haven’s approximately 8,600 households. The campaign and sign-up period begins November 16, 2017 and will run through April 5, 2018.

History of DOW Chemical’s Involvement

In 2008, DOW Chemical started an R&D effort to produce shingles that could serve as a solar panel and be directly integrated into a roof. DOW’s first efforts were installed in over 1,000 locations in 18 states. Then, in 2015, DOW switched to a lower cost solar technology which, they believed, would be more commercially viable. The new technology also had the benefit of being more efficient.

DOW Chemical has patented the new technology and it is this technology that is being licensed by Real Goods Solar, Inc. (NASDAQ:RGSE). Real Goods Solar, Inc. (NASDAQ:RGSE) has agreed to absorb all commercial aspects of the deal including supply chain management, marketing, sales, installation and warranty. It is believed that sales will commence in the first half of 2018.

RGSE Stock Performance

Real Goods Solar, Inc. (NASDAQ:RGSE) shares, adjusted for dilution, have been battered over the past two years. In 2016 they were trading over $100 and spent much of 2016 with their shares valued at twice those levels. However, for the past few months the solar energy based company has struggled to keep its share value above $1 – typically the threshold for being listed on the NASDAQ Market.

The past year has seen RGSE stock hit a high of over $86, and a low of $0.60. Sales growth was impressive from 2012 through 2014 as the figure rose from $44 million to $70.8 million. Unfortunately the company posted a disappointing $17.4 million for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RGSE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Remark Holdings, Inc. (NASDAQ:MARK)

Remark Holdings, Inc. (NASDAQ:MARK) AI Key To Future Growth

Remark Holdings, Inc. (NASDAQ:MARK)

Shares of Remark Holdings, Inc. (NASDAQ:MARK) gained 5.98% as investors reacted to the company’s 3D augmented reality product being selected as the core technology behind Sina Weibo new mobile application. Developed by the company’s wholly-owned subsidiary, KanKan, the 3D facial tracking technology can track and recognize movements of various facial features.

Remark Holdings, Inc. (NASDAQ:MARK)

Sina Weibo Collaboration

According to the company’s Chief Executive Officer, Kai-Shing Tao, integration of the technology in Sina Weibo app, SuishouPai app, demonstrates the company’s ability to monetize its technologies. The use of the facial recognition technology should also help Remark Holdings better understand various facial expression which could lead to further improvements in the AI technology.

“We not only created a facial tracking system that we believe is far superior to existing technologies, but we also created 3D filters that can be used socially among friends or used to identify business opportunities in various industries, such as in the cosmetics field,” Tao in a statement.

Some observers believe that the value of the Sina Weibo deal has yet to be fully factored into the stock price of Remark Holdings, Inc. (NASDAQ:MARK). The share price has struggled to break through the $3 -$4.50 trading range despite the value of the assets that the company owns.

The stock is currently rated as a ‘strong buy’ by one analyst firm according to data compiled by Zacks Investment Research.

KanKan AI Prospects

KanKan has inked lucrative deals with tech giants Alibaba Group Holding Ltd (NYSE:BABA), Tencent Holdings Ltd (OTCMKTS:TCEHY) and Sina Weibo, something that could have catapulted the stock up the charts. However, that has not been the case. The management has already indicated that the recently announced deals have the potential to take the company’s artificial revenue from zero as of the start of the year, to $20 million as of next year.

The expected revenue could be much higher as tech giants continue to come up with unique ways of integrating artificial intelligence into their operations and products. The Remark Holdings subsidiary could continue to elicit interest given the investment it has made on the emerging technological spectacle.

“Artificial intelligence is the most exciting and disruptive force in technology today. It has the power to rapidly change business fundamentals. Remark’s AI technology platforms are on the forefront,” said Tao.

A further testament to Remark Holdings, Inc. (NASDAQ:MARK) credibility on AI is the naming of KanKan latest product, Heterogeneous Multi-Intelligence System, among the top three in Alibaba’s ‘Best AI Products’.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MARK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Bon-Ton Stores Inc (NASDAQ:BONT)

Bon-Ton Stores Inc (NASDAQ:BONT) Guns Higher on New Financing

Bon-Ton Stores Inc (NASDAQ:BONT)

Shares of Bon-Ton Stores Inc (NASDAQ:BONT) have spiked up over 80% in trading after the company announced that it has amended its $880 million credit facilities which should provide the retailer with immediate flexibility and additional liquidity. Observers believe the amended credit facility was a requirement for the company to be able to increase inventories in expectation of the Christmas sales season.

Bon-Ton Stores Inc (NASDAQ:BONT)

Nancy Walsh, Bon-Ton Stores Inc (NASDAQ:BONT)’s Executive Vice President and Chief Financial Officer, commented, “We are pleased with this amendment which immediately provides us with additional liquidity cushion and strengthens our financial flexibility through the holiday season. We appreciate the ongoing support of our bank group as our team continues to execute key operational and financial initiatives focused on positioning the business for both near- and long-term profitable growth.”

Company Performance

Sales have been on the decline for Bon-Ton Stores Inc (NASDAQ:BONT). While not dramatic, the decrease in sales has been steady. In 2013 the company reported $2.98 billion in sales. That sales performance was followed, yearly, by $2.83, $2.82, $2.79, and $2.67 billion for FY2017. The last five years have also seen per share losses for BONT shareholders. The last two years were the largest, (-$2.90) in 2016, and (-$3.18) for FY2017.

BONT Stock Review

The York, PA-based retailer announced the deal yesterday with less than an hour left in trading. Within 30 minutes BONT stock jumped from $0.33 to over $0.70. Then this morning the stock gapped up to open at $0.80 before hitting an inter-day high of $1.19. BONT stock volume is extraordinarily heavy. Over 37.8 million shares have traded hands on a stock that normally sees barely more than 500,000 shares traded daily.

Still, Bon-Ton Stores Inc (NASDAQ:BONT) shareholders have had a rough year as the shares have lost over 60% of their value prior to today’s price action. BONT stock still has further to travel if it is to challenge the existing 52-week high of $1.98 which was hit last November. The sudden spike has impacted the stock’s Relative Strength Index which is standing above 85 – a figure well inside the “overbought” area of the indicator.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BONT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) Catches Market by Surprise

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) shares are up almost 50%, to $0.53, on heavy volume despite the lack of any publicly available news that could account for such extreme price action. The company’s last press release was in August of 2017.

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) is a molecular diagnostics company that develops, markets, and sells advanced testing solutions for the food safety testing market. Their lead product is the Atlas® Detection Assay that integrates proprietary technologies into their Atlas System which automates all aspects of the diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.

Roka Bioscience Asset Sale

In August, Roka Bioscience Inc (NASDAQ:ROKA) announced that it entered into an asset purchase agreement with Rokabio, Inc., a wholly-owned subsidiary of Institute for Environmental Health, Inc., for the sale of substantially all of the assets of Roka Bioscience in an all-cash transaction for an aggregate purchase price of $17.5 million. Shares lost 9% the day the asset sale was announced and have been in a downward trajectory until a few days ago when shares gapped up and briefly traded about the psychologically important $2.50 level.

ROKA Stock Performance

The market capitalization of Roka Bioscience Inc (NASDAQ:ROKA) is less than $7 million with a float of 4.33 million shares. Investors have not had a good year. Year to date, ROKA shares have lost around 75% and, prior to today, lost over 34%. Reports have analyst’s consensus, one year price target at $10.

Sales have been improving every year. In 2012, the company reported just $100,000 in sales but that number improved each year and, in 2016, the company posted $7.2 million in sales. However, the upward momentum has not been seen in earnings. For 2016 the company reported a per share loss of (-$17.42), which was better than the loss of (-$21.18) reported in 2015, and the per share loss of (-$29.30) reported in 2014.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ROKA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Pluristem Therapeutics Inc. (NASDAQ:PSTI),

Patent Pushes Pluristem Therapeutics Inc. (NASDAQ:PSTI) Higher

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI), headquartered in Israel, established a new 52-week high today of $2.02 after the company announced that the European Patent Office has issued the company a patent titled, “Methods for Treating Radiation or Chemical Injury” for its PLX-R18 cell therapy. Volume for the biotechnology stock, up 9% in today’s trading, was heavy – over five times the daily average traded.

Pluristem Therapeutics Inc. (NASDAQ:PSTI),

Pluristem Patent

PLX-R18 is designed to treat bone marrow that is unable to produce enough blood cells due to a variety of causes, including acute radiation syndrome (ARS), certain cancers or cancer treatments, or immune-mediated bone marrow failure. Pluristem Therapeutics Inc. (NASDAQ:PSTI) currently holds several patents worldwide to cover placental 3D-expanded cells in the treatment of impaired hematopoietic systems when a bone marrow, cord blood, or peripheral blood transplant takes place.

Yaky Yanay, Co-CEO and President of Pluristem Therapeutics Inc. (NASDAQ:PSTI) stated “PLX-R18 cells have shown the ability to trigger regeneration of the hematopoietic system, thereby supporting the recovery and production of white blood cells, red blood cells and platelets. With its capabilities, we believe that PLX-R18 has the potential to treat a broad range of hematologic indications, which together constitute a substantial global market.”

PSTI Stock Performance

Three investment firms follow Pluristem Therapeutics Inc. (NASDAQ:PSTI) and all three rate PSTI shares as a “Strong Buy”. Their consensus, one year price target is $3.50. Investors have been hot on the stock. Over the past year PSTI stock is up over 30% and is up over 60% for the quarter. That upward momentum has resulted in a Relative Strength Index figure of 73 – prior to today’s trading. Traders believe that a figure above 70 represents an “overbought” condition.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) reported no sales for FY2017 after posting $2.8 million in 2016. The per share loss for FY2017 was (-$0.32) which followed a loss of (-$0.29) in 2016. Of note is a consistent expansion of the number of outstanding shares. For 2013, 55.48 million shares were outstanding. The dilutive expansion of the number of shares has increased every year and for 2017 the figure stands at 87.43 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSTI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Strata Skin Sciences, Inc. (NASDAQ:SSKN) Rebounding

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences, Inc. (NASDAQ:SSKN) stock is up over 20% today after a week that has seen the Skin Science company lose over 30% of its value. SSKN stock is experiencing heavy volume during this rebound as more than two million shares have traded hands for a stock that has an average daily volume of less than 200,000.

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences

Strata Skin Sciences, Inc. (NASDAQ:SSKN), headquartered in Horsham, PA, is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN™ MicroSystem, marketed specifically for the intended use of micropigmentation; and Nordlys, a multi-technology aesthetic laser device.

SSKN Stock Review

Interestingly, the current market price for SSKN shares is below published figures of the company’s cash per share which is posted at $1.51. It has a book to share ratio of $4.99.

Yesterday SSKN shares hit a new 52-week low – hitting $1.10. Their 52-week high of $5.40 was achieved last April and the shares spiked again in May though not enough to establish a new high.

Sales have been increasing at a rapid pace. In 2014, Strata Skin Sciences, Inc. (NASDAQ:SSKN) reported sales at $900,000 but that number increased the following year and also in 2016 when the company posted a figure of $31.8 million. However losses have plagued the shareholders over the past five years. Last year’s per share loss of (-$1.57) was, by far, the smallest in the company’s history and could serve as a signal that the company has turned the corner.

One must always be on the lookout for equity diluting events when it comes to biotech firms and Strata Skin Sciences, Inc. (NASDAQ:SSKN) is no exception. In 2012 there were 620,000 shares outstanding. That number has increased every year and for 2016 was listed at 2.12 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SSKN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Investors Flock to U.S. Energy Corp. (NASDAQ:USEG)

U.S. Energy Corp. (NASDAQ:USEG)

U.S. Energy Corp. (NASDAQ:USEG) is worth only $6.5 million but so far today its stock is making news for all the right reasons. ESEG stock is up over 33% at 2 PM EST. Share volume is extraordinarily heavy – over 100 times the average.

U.S. Energy Corp. (NASDAQ:USEG)

Investors are jumping on board the energy company after it announced that it will participate in the upcoming horizontal drilling program on its existing acreage position targeting the development of the Georgetown formation in Zavala and Dimmit Counties, Texas. The development program will take place on acreage positions previously developed for shallower horizons. Operations are expected to begin in late October 2017 and the initial well will be drilled as a dual lateral.

David Veltri, Chairman and CEO of U.S. Energy Corp. (NASDAQ:USEG), stated, “We are pleased to announce our participation in the upcoming drilling program and excited for the future prospects of U.S. Energy as we continue our transition from being focused on restructuring the Company’s balance sheet to becoming a growth-oriented E&P Company. Our recently announced restructuring initiatives along with the completion of recent asset sales will allow us to re-deploy capital to focus on significant growth opportunities and position U.S. Energy to maximize returns for shareholders. This is the first newly drilled well that U.S. Energy has participated in since early 2015, and we look forward to evaluating and participating in other highly accretive development projects that are focused on capital returns and cash generation.”

USEG Stock Performance

U.S. Energy Corp. (NASDAQ:USEG) stock has been given a one year consensus price target of $3.90 by analysts. The stock is still around 50% off its 52-week high of $2.74 but is well north of its 52-week low of $0.60. For the year, shareholders have lost over 40% but over the last month USEG stock has gained over 25%. The stock has a Relative Strength Index figure of 77. Typically, traders believe that a figure over 70 indicates an “overbought” condition.

Sales have been in decline for the past three years. In 2014, U.S. Energy Corp. (NASDAQ:USEG) reported $32.4 million in sales, followed by annual figures of $10.3 million, and $5.7 million for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $USEG and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.


Fatal error: Call to undefined method WP_Image_Editor_Imagick::get_error_message() in /home3/c5d1p0f8/public_html/wp-content/plugins/core-extend/include/aq_resizer.php on line 157